about
Brn-2 expression controls melanoma proliferation and is directly regulated by beta-cateninThe Brn-2 transcription factor links activated BRAF to melanoma proliferationAnalysis of the genome to personalize therapy for melanomaOncogenic mutations in GNAQ occur early in uveal melanomaDabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaMelanoma: from mutations to medicineImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeThe genetics of uveal melanoma: current insightsMucosal melanomas in the elderly: challenging cases and review of the literature.SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanomaThe protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanomaThe genetics of uveal melanoma: an emerging framework for targeted therapyMucosal melanomas: a case-based review of the literature.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesDabrafenib and its potential for the treatment of metastatic melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanomaMolecular bases of cutaneous and uveal melanomas.Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.The current state of targeted therapy in melanoma: this time it's personalHigh levels of Hdmx promote cell growth in a subset of uveal melanomas.Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.Molecular pathology of uveal melanomaActivation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.Episodic Src activation in uveal melanoma revealed by kinase activity profiling.Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads - case report and review of literature.Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis.Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
P2860
Q24317170-33D35309-EC24-4584-86BE-8F5EF471D359Q24599712-688D73D5-706F-40C1-92E9-FE98F93B4252Q24601008-8668FE05-D338-456D-8C76-5C84AA2DAC9AQ24658558-507E51F9-5F5D-4DCB-823D-6DD8891407E8Q26745933-C603FFA6-5429-42F6-A866-03717C9ABF37Q27024061-499ABE3B-026C-49E0-96DF-D68CF0AAB2F3Q27334924-70F2937D-99A6-4F18-90E2-E5D3485CFB88Q28073150-E5E9368C-4061-40E6-BA93-7DA1638299B3Q33769490-EF509A47-F5B3-430A-AE8F-01A814AFB765Q33853615-CEAFFFAE-342F-4810-9023-C697AC917965Q34130528-68C2EFF5-3513-4CCD-BE5C-C429B3D2A94CQ34249080-E42E8F91-E72A-4F64-A1AD-7E6142CED4B4Q34620895-66AFE56E-A396-4201-8CCA-00D3A341F8A5Q34639532-28A988F2-5737-4D76-A5CB-D23B777DEE30Q34646614-EB311116-73FA-435B-B8CF-1D4123A168FBQ34662717-FA00963C-CE37-4391-B9A0-DB9AD91F64A6Q35174214-99787ADF-6A95-409E-B449-3568EC693A82Q35519172-B7C40C30-3674-4B0A-933A-87F3CF8A533EQ35588657-8C8F63A7-6B7F-47E7-B337-1D47DF9D597AQ35774475-2ED99906-AB72-4EB6-A3B9-D9682EB8A8BDQ35878248-343A5E32-2FAE-4ED2-9F96-96774A60FE40Q36206473-73FBC0C9-0886-4B07-8633-7F68028252C2Q36468749-4B327084-B085-4AD7-917B-2A9CAA413545Q36615059-1690C889-58DB-4439-9E12-0E7050621EA5Q36615986-EDC18F95-699B-4B5F-8E00-0B2534F76FDCQ37655079-435D11A2-3CCE-4447-9DD2-BAE1C4BB7FA0Q38833742-C5FCF97A-7E92-4458-98C8-E878544280D2Q38978135-05803B57-64A7-40F2-A145-48A9023D69F5Q39830805-60059CED-D1B1-442C-B7DE-031269A1D1A5Q47142357-7FECB90E-1450-4975-B5C5-63F0CE27A10BQ47246686-51885F2A-D0BF-4143-B7FC-9F2D7CE9FF55Q52640287-DB269BBF-1B49-4780-91E2-F70215E49B4C
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Lack of BRAF mutations in uveal melanoma.
@en
Lack of BRAF mutations in uveal melanoma.
@nl
type
label
Lack of BRAF mutations in uveal melanoma.
@en
Lack of BRAF mutations in uveal melanoma.
@nl
prefLabel
Lack of BRAF mutations in uveal melanoma.
@en
Lack of BRAF mutations in uveal melanoma.
@nl
P2093
P1433
P1476
Lack of BRAF mutations in uveal melanoma.
@en
P2093
Daniel Speiser
Danielle Liénard
Donata Rimoldi
Ferdy J Lejeune
Jean-Charles Cerottini
Leonidas Zografos
Suzanne Salvi
P304
P407
P577
2003-09-01T00:00:00Z